You are invited to a special forum on Accelerating Drug Discovery: New Approaches to Public - Private Partnerships.

The forum will be held on Tuesday, May 2nd, 7:00 - 8:30 PM, in <u>Abbott Auditorium</u>, <u>Pancoe Hall</u>, on the Evanston campus. It will be preceded by a reception with hors d'oeuvres, wine and beer, at 6:00PM, in the 1st floor of <u>Silverman Hall for Molecular Therapeutics and Diagnostics</u>.

The featured speaker will be Peter Schultz, PhD (Scripps Family Chair Professor, CEO & Vice Chair Research Administration, California Campus, The Scripps Research Institute). The forum will also include panelists from the greater Chicago area drug discovery and development community.

Peter Schultz is the founder and former director of <u>GNF</u>, and the founding director of the <u>California Institute for Biomedical Research</u> (Calibr), established in 2012. In August 2014, <u>Nature Biotechnology</u> ranked Peter Schultz the #1 top translational researcher in 2013. Dr. Schultz will discuss Scripps/ Calibr's partnering strategy for bringing several first-in-man agents, which were discovered in the academic setting, into clinical trials.

Dr. Schultz is the author of ~600 scientific publications, has trained over 300 coworkers, and has received numerous awards including the Alan T. Waterman Award, NSF, ACS Award in Pure Chemistry, Wolf Prize in Chemistry, Paul Ehrlich and Ludwig Darmstaedter Award, ACS Arthur C. Cope Award, Solvay Prize, and Wieland Prize. He is a fellow of the National Academy of Sciences, USA and the Institute of Medicine of the National Academy of Sciences and is active on many editorial and scientific advisory boards. He is a founder of Affymax Research Institute, Symyx Technologies, Syrrx, Kalypsys, Phenomix, Ilypsa, Ambrx, Wildcat Discovery Technologies, and Ardelyx, which have pioneered the application of molecular diversity technologies to challenges in energy, materials and human health.

This event is hosted by Northwestern University's <u>Center for Developmental Therapeutics</u> in the <u>Chemistry of Life Processes Institute</u> and the <u>Innovation and New Ventures Office</u>.

For more information please contact Tiffany Leighton Ozmina, tiffany.ozmina@northwestern.edu

Best regards,

Thomas O'Halloran, PhD

Charles E. and Emma H. Morrison Professor Weinberg College of Arts and Sciences Director, Chemistry of Life Processes Institute

Thomas V. offellows

Director, NCI Chicago Region Physical Science Oncology Center

Northwestern University